All News
Legal (Not So) Merry-Go-Round of Alendronate Atypical Fractures
Dr. Gregory Curfman, MD (Executive editor of JAMA) writes on the chronological legal progress of a lawsuit stemming from rare instances of atypical femoral fractures associated with bisphosphonate (alendronate) use.
Read Article
Antacids can Diminish Bone Density
d
EurekAlert!
Proton pump inhibitors (PPIs), a specific class of antacid drugs, are among the most widely used medications of all. They are frequently prescribed to many groups of patients, including those with rheumatism.
Read Article
Consensus Statements on Vitamin D
The “Controversies in Vitamin D” International Conference has published their proceedings on vitamin D metabolism, assessment, actions, and supplementation. Interestingly, optimal levels of 25-hydroxy vitamin D (25(OH)D) are still being debated.
Read Article
Infectious Mortality in Autoimmune Rheumatic Disorders
Infectious conditions are a significant cause of mortality in autoimmune rheumatic diseases (ARD). Among patients hospitalized with an infection, we compared in-hospital and long-term (3-year) mortality between those with and without ARD.
Small-molecule Drugs to Treat Systemic Lupus Erythematosus
A metanalysis of randomized controlled trials (RCTs) on treatments of systemic lupus erythematosus (SLE), confirm the efficacy of several targeted small-molecule drugs.
Single center EHR study of 5 064 pts w/ pre-diabetes compared those starting metformin (1154) vs 13 877 non-users w/ ~4 yrs F/U. Incidence of future gout was lower w/ metformin use (7.1 vs 9.5/1000PYs; HR 0.68); with no change in SUA or CRP https://t.co/CXdcEdWXhW https://t.co/j0ktehf9Sm
Dr. John Cush RheumNow ( View Tweet)
2023 Top 3 paper from JAMA Derm - 122 plaque psoriasis pts (mild-mod w/ PASI=3.1) & low vit D levels (~14.9), Rx w/ PBO vs vit D 20 000 IU/wk x 4 mos during winter; no signif vit D Rx benefit for PASI, MD global, DLQI or 25-OH levels(< than expected) https://t.co/8W5abvydY6 https://t.co/rKJjkiHwC6
Dr. John Cush RheumNow ( View Tweet)
My Cancelled Lecture (5.11.2024)
In lieu of this weeks podcast, Dr. Jack Cush records his "Life Lessons (that keep changing) in Rheumatology Lecture. A lecture recently cancelled because some of this content was objectionable? (I dont think so!)
https://t.co/8iObw8cE5S https://t.co/k06P4mMwmD
Dr. John Cush RheumNow ( View Tweet)
Inflammatory Myositis market size was valued at ~$575 million USD in 2022 with 184,204 confirmed IMM cases in the 7MM. In the USA there were 90,064 cases in 2022 https://t.co/uLtxOYGrLr https://t.co/W5TApBDV3C
Dr. John Cush RheumNow ( View Tweet)
Metanalysis of 26 reports and 195 juvenile Dermatomyositis pts (age 4.9 yrs) treated w/ JAK inhib (tofa, rux, & bari); Good improvement in 90%, 69% & 93%, respectively. JAK indication refractory skin dz (35%) or muscle involvement (29%). TIME FOR RCTs!! https://t.co/0aaLV7iCWR https://t.co/DLGRqqmIyX
Links:
Dr. John Cush RheumNow ( View Tweet)
National French study finds post COVID Vaccine the IR of PMR (179 cases; RR 7.1/mill) & GCA (54 cases; RR 2.1 /million) were reported 7-10d post vax. These #s are below population incidence rates (1-20/mill for GCA) https://t.co/XvaoWhqs2g https://t.co/BFDy2WKcLx
Dr. John Cush RheumNow ( View Tweet)
Retrospective, cross-sectional study from the Osteoarthritis Initiative (OAI), 2607 pts (age 64yrs; BMI 28.5). After 48 mos regular bicycling yielded signif less knee pain (HR 0.83), Xray OA (0.91) & Sxs OA (0.79), Encourage Bicycling! https://t.co/ktocvwujwt https://t.co/DOfE1BFRJh
Dr. John Cush RheumNow ( View Tweet)
Review article of Interstitial Lung Dz Assoc w/ Systemic Sclerosis. SSc-ILD prevalence ranges 25-95%; ILD is a main cause of morbidity and mortality, contributing to 35% of deaths https://t.co/aM5O6lwQLw https://t.co/RG6xe5rVE7
Links:
Dr. John Cush RheumNow ( View Tweet)
Since 2010, use of RTX has increased & AZA decreased in GPA/MPA. French national insurance study of 977 GPA/MPA in 2010-12 vs 1131 GPA/MPA in 2014–2017 saw incr RTX, decr AZA, but stable use MTX, CTX, steroids over time https://t.co/ICtDqxthAN https://t.co/bFvOL3GGmf
Dr. John Cush RheumNow ( View Tweet)
Alot of murky "research" on Platelet-rich plasma (PRP). This RCT of120 pts having anterior cruciate ligament reconstruction (half randomized to PRP) shows no PRP benefit, no significant improvement of knee symptoms & function post ACLR https://t.co/qscBvywWLS https://t.co/jSohaMhBnY
Dr. John Cush RheumNow ( View Tweet)
Retrospective cohort study compared 5825 #AS pts vs 28,356 matched controls; showed an increased risk of pulmonary embolism w/ AS; not present pre-Dx ((0.4% vs 0.2%), but incr post-AS Dx (PE IR 11.6 vs 6.8/10KPY: adj HR 1.70;; p<0.001) https://t.co/Tsd77iUsjC https://t.co/sd6wbtuaqw
Dr. John Cush RheumNow ( View Tweet)
In animal models, IL-22 may have protective effects against pulm fibrosis. Study of 66 new #RA pts (1/2 w/ ILD) & 14 controls. Serum IL-22 was signif lower in RA-ILD; and was inversely correlated with the severity of RA-ILD https://t.co/Rmr5N2JznH https://t.co/OZ1ZrgGXC3
Links:
Dr. John Cush RheumNow ( View Tweet)
K Kuhn et al: Altered tryptophan catabolism by microbiome may contribute to inflammatory arthritis. Tryptophan increases indole leading to ncreases in serum IL-6, TNF, and IL-1β; splenic RORγt+CD4+ T cells, & IL-23 and IL-17 production https://t.co/Bqm5ecvGR5 https://t.co/O1jCSqFICr
Dr. John Cush RheumNow ( View Tweet)
The EMAs CHMP has recommended for approval Two biosimilars, Tofidence (tocilizumab) and Wezenla (ustekinumab) https://t.co/mREclYdeCk https://t.co/zQX00Ys8oH
Dr. John Cush RheumNow ( View Tweet)
MGH study compared 1148 acute CPPD vs 3730 controls (mean 73 yrs) found 2 fold more fractures (mostly wrist); 11.7 vs 5.5/1000 PYs (HR 1.8) in pseudogout pts (also had more steroids & OP) https://t.co/HhCV6fYubF https://t.co/3bcbvSzzPo
Dr. John Cush RheumNow ( View Tweet)